Asymchem Laboratories (Tianjin) Co., Ltd.

SZSE:002821 Stock Report

Market Cap: CN¥29.4b

Asymchem Laboratories (Tianjin) Valuation

Is 002821 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 002821 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 002821 (CN¥88.9) is trading above our estimate of fair value (CN¥88.45)

Significantly Below Fair Value: 002821 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 002821?

Key metric: As 002821 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 002821. This is calculated by dividing 002821's market cap by their current earnings.
What is 002821's PE Ratio?
PE Ratio41x
EarningsCN¥769.03m
Market CapCN¥29.42b

Price to Earnings Ratio vs Peers

How does 002821's PE Ratio compare to its peers?

The above table shows the PE ratio for 002821 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average89.3x
600566 Hubei Jumpcan Pharmaceutical
9.9x10.7%CN¥27.4b
000513 Livzon Pharmaceutical Group
17.2x10.2%CN¥30.4b
600518 Kangmei Pharmaceutical
131.8xn/aCN¥32.7b
002603 Shijiazhuang Yiling Pharmaceutical
198.2x48.6%CN¥28.8b
002821 Asymchem Laboratories (Tianjin)
41x29.9%CN¥29.4b

Price-To-Earnings vs Peers: 002821 is good value based on its Price-To-Earnings Ratio (41x) compared to the peer average (89.3x).

Price to Earnings Ratio vs Industry

How does 002821's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
002821 41.0xIndustry Avg. 29.9xNo. of Companies30PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 002821 is expensive based on its Price-To-Earnings Ratio (41x) compared to the CN Pharmaceuticals industry average (29.9x).

Price to Earnings Ratio vs Fair Ratio

What is 002821's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

002821 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio41x
Fair PE Ratio34.8x

Price-To-Earnings vs Fair Ratio: 002821 is expensive based on its Price-To-Earnings Ratio (41x) compared to the estimated Fair Price-To-Earnings Ratio (34.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 002821 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥88.90
CN¥94.33
+6.1%
22.9%CN¥127.80CN¥59.40n/a10
Nov ’25CN¥81.20
CN¥93.50
+15.2%
24.0%CN¥127.80CN¥52.40n/a11
Oct ’25CN¥83.73
CN¥86.07
+2.8%
25.4%CN¥130.30CN¥52.40n/a11
Sep ’25CN¥63.67
CN¥90.80
+42.6%
22.6%CN¥130.30CN¥56.30n/a11
Aug ’25CN¥74.08
CN¥95.64
+29.1%
21.4%CN¥135.10CN¥56.30n/a11
Jul ’25CN¥65.22
CN¥99.43
+52.4%
20.9%CN¥145.00CN¥61.00n/a11
Jun ’25CN¥76.69
CN¥99.43
+29.6%
20.9%CN¥145.00CN¥61.00n/a11
May ’25CN¥82.65
CN¥99.43
+20.3%
20.9%CN¥145.00CN¥61.00n/a11
Apr ’25CN¥87.00
CN¥127.74
+46.8%
25.5%CN¥184.00CN¥85.00n/a10
Mar ’25CN¥102.24
CN¥152.54
+49.2%
23.4%CN¥197.56CN¥91.40n/a9
Feb ’25CN¥90.72
CN¥159.52
+75.8%
22.7%CN¥197.56CN¥91.40n/a9
Jan ’25CN¥116.10
CN¥166.73
+43.6%
18.6%CN¥197.56CN¥106.57n/a9
Dec ’24CN¥141.00
CN¥170.73
+21.1%
17.4%CN¥197.56CN¥106.57n/a9
Nov ’24CN¥146.21
CN¥170.03
+16.3%
17.6%CN¥197.56CN¥106.25CN¥81.209
Oct ’24CN¥151.70
CN¥155.20
+2.3%
21.5%CN¥200.30CN¥100.13CN¥83.739
Sep ’24CN¥131.67
CN¥155.86
+18.4%
21.6%CN¥200.30CN¥100.13CN¥63.679
Aug ’24CN¥125.79
CN¥159.22
+26.6%
23.2%CN¥196.74CN¥100.13CN¥74.089
Jul ’24CN¥117.86
CN¥167.63
+42.2%
29.8%CN¥268.60CN¥100.13CN¥65.229
Jun ’24CN¥136.02
CN¥175.30
+28.9%
27.2%CN¥268.60CN¥100.13CN¥76.698
May ’24CN¥126.45
CN¥175.97
+39.2%
26.7%CN¥268.60CN¥100.13CN¥82.658
Apr ’24CN¥133.33
CN¥188.15
+41.1%
28.4%CN¥288.10CN¥100.13CN¥87.007
Mar ’24CN¥143.76
CN¥195.53
+36.0%
30.6%CN¥323.20CN¥117.42CN¥102.247
Feb ’24CN¥165.96
CN¥195.03
+17.5%
31.4%CN¥323.20CN¥109.49CN¥90.727
Jan ’24CN¥148.00
CN¥195.03
+31.8%
31.4%CN¥323.20CN¥109.49CN¥116.107
Dec ’23CN¥137.48
CN¥195.03
+41.9%
31.4%CN¥323.20CN¥109.49CN¥141.007
Nov ’23CN¥150.17
CN¥209.29
+39.4%
26.0%CN¥323.20CN¥145.70CN¥146.216

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Sichuan Kelun Pharmaceutical

CN¥47.5b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥31.84

7D

-3.9%

1Y

14.4%

Dong-E-E-JiaoLtd

CN¥37.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥58.44

7D

-2.0%

1Y

18.4%

China Resources Double-Crane PharmaceuticalLtd

CN¥22.3b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥22.24

7D

2.3%

1Y

23.4%